A detailed history of Vanguard Group Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 4,357,540 shares of MGNX stock, worth $14.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,357,540
Previous 4,135,319 5.37%
Holding current value
$14.2 Million
Previous $17.6 Million 18.43%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.0 - $5.55 $666,663 - $1.23 Million
222,221 Added 5.37%
4,357,540 $14.3 Million
Q2 2024

Aug 13, 2024

BUY
$3.31 - $18.51 $1.51 Million - $8.47 Million
457,641 Added 12.44%
4,135,319 $17.6 Million
Q1 2024

May 10, 2024

SELL
$9.77 - $21.47 $6.17 Million - $13.6 Million
-631,716 Reduced 14.66%
3,677,678 $54.1 Million
Q4 2023

Feb 14, 2024

SELL
$4.48 - $10.11 $472,774 - $1.07 Million
-105,530 Reduced 2.39%
4,309,394 $41.5 Million
Q3 2023

Nov 14, 2023

BUY
$4.48 - $6.19 $163,054 - $225,291
36,396 Added 0.83%
4,414,924 $20.6 Million
Q2 2023

Aug 14, 2023

SELL
$4.62 - $7.54 $415,204 - $677,627
-89,871 Reduced 2.01%
4,378,528 $23.4 Million
Q1 2023

May 15, 2023

BUY
$4.82 - $7.24 $115,848 - $174,013
24,035 Added 0.54%
4,468,399 $32 Million
Q4 2022

Feb 10, 2023

BUY
$3.34 - $6.98 $875,490 - $1.83 Million
262,123 Added 6.27%
4,444,364 $29.8 Million
Q3 2022

Nov 14, 2022

BUY
$3.01 - $5.22 $756,349 - $1.31 Million
251,279 Added 6.39%
4,182,241 $14.5 Million
Q2 2022

Aug 12, 2022

SELL
$2.25 - $9.99 $227,873 - $1.01 Million
-101,277 Reduced 2.51%
3,930,962 $11.6 Million
Q1 2022

May 13, 2022

BUY
$8.12 - $16.9 $698,815 - $1.45 Million
86,061 Added 2.18%
4,032,239 $35.5 Million
Q4 2021

Feb 14, 2022

BUY
$15.91 - $21.88 $796,104 - $1.09 Million
50,038 Added 1.28%
3,946,178 $63.3 Million
Q3 2021

Nov 12, 2021

SELL
$19.74 - $28.7 $886,799 - $1.29 Million
-44,924 Reduced 1.14%
3,896,140 $81.6 Million
Q2 2021

Aug 13, 2021

BUY
$20.49 - $35.63 $80.8 Million - $140 Million
3,941,064 New
3,941,064 $106 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.